# Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

> **NCT05243329** · PHASE2 · UNKNOWN · sponsor: **Halucenex Life Sciences Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Treatment Resistant Disorders
- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT05243329
- **Lead sponsor:** Halucenex Life Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-03
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243329, "Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05243329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*